ResVerlogix: A Biotech on the Block
During the recent BIO CEO & Investor Conference in New York , you couldn't throw a gene sequencer across the lobby of the Waldorf Astoria without hitting the chief executive of a company with strong science and no profits. It's little wonder that when confronted by the long, costly, and risky drug development process, some small startups are hoping to be acquired by a major player and cash in. Then they can worry about the tedious business of getting drugs approved. And Big Pharma may be warming to the idea.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.